EMA/CHMP December 2018 meeting highlights

14 December 2018

At its December 2018 meeting, the European Medicines Agency’s the Committee for Medicinal Products for Human Use (CHMP) recommended seven medicines for approval.

Two orphan medicines received a positive opinion from the Committee: Besremi (ropeginterferon alfa-2b), from Austrian firm AOP Orphan Pharmaceuticals, for the treatment of polycythemia vera without symptomatic splenomegaly, and Trecondi (treosulfan), from Germany’s medic Gesellschaft, for the conditioning treatment prior to allogeneic haematopoietic stem cell transplantation.

There were two positive opinions for Japan’s Shionogi (TYO: 4507). The CHMP recommended granting a marketing authorization for Lusutrombopag Shionogi (lusutrombopag), for the treatment of severe thrombocytopenia in adults with chronic liver disease undergoing invasive procedures, and Rizmoic (naldemedine) for the treatment of opioid-induced constipation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK